Moreover, the researchers could evidence, after treatment with Nivolumab, an increased infiltration of human TIL, T-cells, and CD8+ T-cells in PDX as well as an increased secretion of IFN-ɣ, thus demonstrating an anti-tumor immune response. This evidence concerns the gene CD8A and neoplasm.